The Spanish HIV BioBank: a model of cooperative HIV research

García-Merino, Isabel; Cuevas, Natividad de las; Jiménez, José Luís; Gallego, Jorge; Gómez, C. Colomo; Prieto, Cristina Obaya; Serramía, Ma Jesús; Lorente, Raquel; Muñoz‐Fernández, María Ángeles; BioBank, Spanish Hiv

doi:10.1186/1742-4690-6-27

Cited by 145 publications

(92 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Ethics Committees of the participating hospitals approved the study and parents and guardians gave their informed consent. Several biological samples were provided by the Spanish HIV BioBank of the Spanish AIDS Research Network [9]. Values were recorded as absolute numbers/percentages, and medians were calculated with their interquartile ranges (IQRs).…”

Section: Methodsmentioning

confidence: 99%

Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients

et al. 2011

View full text Add to dashboard Cite

We evaluated the efficacy, safety and tolerability of etravirine in paediatric patients vertically infected with HIV-1. MethodsA multicentre retrospective study of 23 multidrug-resistant paediatric patients (five children and 18 adolescents) enrolled in the study from 1 September 2007 to 28 February 2010 was carried out. We performed a longitudinal analysis of immunological, virological and clinical data. ResultsThe median age of the patients was 14.2 years [interquartile range (IQR) 12.5-15.8 years]. At baseline, the median HIV-1 RNA was 29 000 (4.5 log 10 ) HIV-1 RNA copies/mL (range 4300-83 000 copies/mL), the median CD4 T-cell count was 445 cells/mL (range 221-655 cells/mL) and the median CD4 percentage was 19.6% (IQR 13.0-31.0). Remarkably, 16 of 23 patients (70%) harboured one or more etravirineassociated resistance mutations. The backbone regimen included at least two fully active drugs in 91% of patients. After etravirine-based therapy, 20 patients (87%) achieved HIV-1 RNAo400 copies/mL and 18 of 23 (78%) achieved HIV-1 RNAo50 copies/mL: three (13%) within the first month, seven (30%) within the first 4 months, and six (26%) between the 5th and 8th months. CD4 T-cell recovery was observed in 19 patients (83%). The median follow-up time was 48.4 weeks .4 weeks); four patients (17%) were exposed to etravirine for 4120 weeks. Three mild/short-term and two moderate skin rashes were observed in the adolescents. Laboratory abnormalities included hypercholesterolaemia (11 of 23 patients), hypertriglyceridaemia (eight of 23 patients), and reduced high-density lipoprotein cholesterol (10 of 23 patients). Adherence was complete in seven patients (30%). No patients showed complete resistance to etravirine after follow-up. However, three of 21 patients (14%) who initially showed intermediate resistance interrupted etravirine treatment because of virological failure. ConclusionsWe observed a sustained antiviral response and improved immunological parameters in multidrugresistant paediatric patients, most of whom had received etravirine as part of salvage regimens with at least two fully active drugs.

show abstract

Section: Methodsmentioning

confidence: 99%

Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Cord blood samples were obtained from 211 healthy neonates directly after delivery in the Hospital General Universitario Gregorio Marañón of Madrid (Spain) and were processed in the Spanish HIVHGM Biobank (38). GA ranged between 25 and 42 wk.…”

Section: Study Population and Sample Preparationmentioning

confidence: 99%

Preterm neonates show marked leukopenia and lymphopenia that are associated with increased regulatory T-cell values and diminished IL-7

et al. 2012

Self Cite

View full text Add to dashboard Cite

IntroductIon: current advances in neonatology have improved survival among preterm and low-birth-weight infants. however, the risk of neonatal death in preterm infants is much greater than in full-term neonates and is frequently associated with infections. Methods: Little is known about the immune status of preterm neonates; therefore, we analyzed the frequency and absolute counts of different immune populations in 211 cord blood samples taken from very-preterm to full-term neonates. results: We found that absolute counts of all the immune subsets analyzed (i.e., monocytes, granulocytes, B cells, natural killer (NK) cells, cD4 + , and cD8 + T cells) were markedly lower in preterm infants than in full-term infants. surprisingly, we observed that regulatory T cells (Tregs) were the only cell subset that did not decrease in preterm infants, and their frequency was even higher than in full-term infants. dIscussIon: Tregs are crucial to maternal-fetal tolerance, but their suppressive role could be also implicated in the leukopenia observed in preterm infants. We did not observe differences in thymic function, but we found that plasma levels of interleukin (IL)-7 and the frequency of its receptor were significantly decreased in preterm infants. Our results could help to identify leukopenia and to implement immune therapies that significantly diminish mortality in preterm neonates. r ecent developments in neonatology and improvements in technology to manage preterm neonates have significantly increased the survival of very-preterm neonates (less than 28 wk of gestation) and very-low-birth-weight infants (less than 1,500 g) (1). However, the relative risk of neonatal death is much greater for preterm infants than for full-term infants, and prematurity has become the leading cause of perinatal morbidity and mortality (2,3). Along with decreasing gestational age (GA), low birth weight is also associated with increased perinatal morbidity and mortality (4). Among the causes responsible for this increased mortality, neonatal sepsis and bronchopulmonary dysplasia are the most frequent causes of death in premature newborns (3).In fact, the most important factors that predispose to infection are prematurity and/or low birth weight.Little is known about innate immunity in premature neonates and the capacity of their immune systems to fight against infections. Several authors have reported differences in phenotype and function of lymphocytes between healthy newborns, children, and adults (5). The immune response of preterm infants is assumed to be immature, although quantitative data on differences in immune capacity between preterm and full-term infants are scant.The objective of this study was to investigate whether the high incidence of infections in preterm infants could be due to an immunodeficiency and, if so, to identify which immune cell populations are implicated in the absence of an adequate immune response. We performed a comprehensive analysis of the frequency and absolute counts of several cell populations in preter...

show abstract

“…Progressors from the HIV unit of the Hospital Universitari Germans Trias i Pujol were selected on the basis of having a CD4 cell count of !200 cells/mL with 10 years or fewer of reported infection. Samples from LTNP patients were provided by the HIV BioBank, using eligibility criteria modified from that reported elsewhere [16]. Eligibility criteria were confirmed HIV infection for 110 years, CD4 cell counts of 1500 cells/mL throughout the course of infection, and viral loads of !5000 copies/mL without antiretroviral therapy.…”

Section: Patients and Samplesmentioning

confidence: 99%

ZNRD1 (Zinc Ribbon Domain–Containing 1) Is a Host Cellular Factor That Influences HIV‐1 Replication and Disease Progression

et al. 2010

View full text Add to dashboard Cite

The Spanish HIV BioBank: a model of cooperative HIV research

Cited by 145 publications

References 7 publications

Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients

Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients

Preterm neonates show marked leukopenia and lymphopenia that are associated with increased regulatory T-cell values and diminished IL-7

ZNRD1 (Zinc Ribbon Domain–Containing 1) Is a Host Cellular Factor That Influences HIV‐1 Replication and Disease Progression

Contact Info

Product

Resources

About